clinical trial · NCT05844527
Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients
Wound of SkinAbdominal WoundMRG-001Saline
brief summary
Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.
started
Nov 20, 2023
primary completion
Sep 1, 2024
completion
Sep 1, 2024
last updated
Sep 8, 2025
detailed description
Subjects will undergo surgical excisions in the abdominoplasty area and will be treated with MRG-001 or placebo for 3 weeks. After 6 weeks, the excision area is harvested for analysis and the study is terminated and the abdominoplasty is performed.
official title
Safety and Efficacy of MRG-001 in Wound Healing and Scar Appearance in Pre-Abdominoplasty Surgical Excisions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol